

[Vinorelbine](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01CA04](#)

EMLc

Indication

Rhabdomyosarcoma primary site ICD11 code: [2C25.Z](#)

INN

Vinorelbine

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 10 mg per mL in 1 mL vial ; 10 mg per mL in 5 mL vial

Oral > Solid > capsule: 20 mg ; 30 mg ; 80 mg (EML)

EML status history

First added in 2021 ([TRS 1035](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Vinorelbine](#)

[DrugBank](#)

[Vinorelbine](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended deletion of vinorelbine 80 mg capsules from the EMLc, and modification of the description of the parenteral forms on the EML and EMLc to 10 mg/mL in 1 mL and 5 mL vials.